Franklin Resources Inc. increased its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 17.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,745,513 shares of the company's stock after purchasing an additional 262,922 shares during the period. Franklin Resources Inc. owned approximately 3.51% of Mineralys Therapeutics worth $21,138,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of MLYS. Caligan Partners LP lifted its holdings in shares of Mineralys Therapeutics by 31.6% in the 3rd quarter. Caligan Partners LP now owns 981,155 shares of the company's stock worth $11,882,000 after acquiring an additional 235,397 shares during the last quarter. American Century Companies Inc. boosted its position in Mineralys Therapeutics by 3.2% during the second quarter. American Century Companies Inc. now owns 743,140 shares of the company's stock valued at $8,695,000 after buying an additional 23,170 shares during the period. Jennison Associates LLC boosted its position in Mineralys Therapeutics by 1.9% during the third quarter. Jennison Associates LLC now owns 696,280 shares of the company's stock valued at $8,432,000 after buying an additional 13,023 shares during the period. Geode Capital Management LLC grew its stake in shares of Mineralys Therapeutics by 6.6% during the third quarter. Geode Capital Management LLC now owns 620,853 shares of the company's stock valued at $7,520,000 after buying an additional 38,527 shares during the last quarter. Finally, Nantahala Capital Management LLC increased its holdings in shares of Mineralys Therapeutics by 60.1% in the second quarter. Nantahala Capital Management LLC now owns 532,506 shares of the company's stock worth $6,230,000 after buying an additional 200,000 shares during the period. 84.46% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Mineralys Therapeutics
In related news, CEO Jon Congleton sold 15,271 shares of Mineralys Therapeutics stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $13.52, for a total transaction of $206,463.92. Following the sale, the chief executive officer now directly owns 895,941 shares in the company, valued at $12,113,122.32. The trade was a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction on Friday, October 11th. The stock was sold at an average price of $13.57, for a total value of $145,972.49. Following the completion of the transaction, the chief financial officer now owns 236,854 shares of the company's stock, valued at approximately $3,214,108.78. This trade represents a 4.34 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 51,510 shares of company stock worth $735,431 over the last quarter. Corporate insiders own 33.24% of the company's stock.
Mineralys Therapeutics Stock Up 4.3 %
Shares of NASDAQ:MLYS traded up $0.51 during midday trading on Friday, hitting $12.34. 512,659 shares of the stock traded hands, compared to its average volume of 179,117. The stock has a market capitalization of $614.15 million, a PE ratio of -3.77 and a beta of 1.55. Mineralys Therapeutics, Inc. has a one year low of $7.29 and a one year high of $16.91. The business's 50 day moving average is $13.12 and its two-hundred day moving average is $12.57.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings data on Monday, November 11th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.30). During the same period last year, the firm posted ($0.57) earnings per share. As a group, sell-side analysts forecast that Mineralys Therapeutics, Inc. will post -3.63 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Mineralys Therapeutics in a research report on Tuesday, November 12th.
Check Out Our Latest Research Report on MLYS
Mineralys Therapeutics Company Profile
(
Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
Recommended Stories
Before you consider Mineralys Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.
While Mineralys Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.